| Arthritis, Psoriatic
Skyrizi vs Simponi ARIA
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Skyrizi vs Simponi Aria with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSimponi Aria has a higher rate of injection site reactions vs Skyrizi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Simponi Aria but not Skyrizi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skyrizi
Simponi Aria
At A Glance
SC injection
Every 8-12 weeks
IL-23 antagonist
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Juvenile polyarthritis
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.
Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter; RA patients must receive concomitant methotrexate.
Juvenile polyarthritis 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter (body surface area-based dosing for patients 2 years of age and older).
Contraindications
- Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient
—
Adverse Reactions
Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash
Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia
Postmarketing Eczema, rash
Most common (>=1%) Upper respiratory tract infection, viral infections, bacterial infections, bronchitis, hypertension, rash, pyrexia, leukopenia
Serious Serious infections (sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis), malignancies, liver enzyme elevations, infusion reactions
Postmarketing Infusion-related reactions, melanoma, Merkel cell carcinoma, anaphylactic reaction, sarcoidosis, interstitial lung disease, skin exfoliation, lichenoid reactions, bullous skin reactions
Pharmacology
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.
Golimumab is a human monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing receptor binding and inhibiting TNF-alpha biological activity, a key mediator of articular inflammation in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skyrizi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Simponi Aria
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Skyrizi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Simponi Aria
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Skyrizi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Simponi Aria
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkyriziView full Skyrizi profile
Simponi AriaView full Simponi Aria profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.